Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide. Although there is general agreement on the first-line use of metformin in most patients with type 2 diabetes, the ideal drug sequence after metformin failure is an area of incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Capuano, Annalisa, Sportiello, Liberata, Maiorino, Maria Ida, Rossi, Francesco, Giugliano, Dario, Esposito, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782406/
https://www.ncbi.nlm.nih.gov/pubmed/24068868
http://dx.doi.org/10.2147/DDDT.S37647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782406/
https://www.ncbi.nlm.nih.gov/pubmed/24068868
http://dx.doi.org/10.2147/DDDT.S37647

Ejemplares similares